Cancer immunotherapy .net

Information on human tumours 3

cancerimmunotherapy@yahoo.com

tumour type

Nasopharyngeal carcinoma

Data in brief: Five-year disease-free survival: 8% without local IL-2 (radiation only) 63% with local IL-2 Phase III study is planned See also press release Zie ook persbericht

2005

Jacobs JJL, Hordijk GJ, Jürgenliemk-Schulz IM, Terhaard CHJ, Koten JW, Battermann JJ, Den Otter W Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2 Cancer Immunol. Immunother. 54 (8): 792 - 798. The therapeutic effect of intratumoural application of IL-2 was studied in patients with stage III-IV nasopharyngeal carcinoma that received radiotherapy. Patients with stage III-IV nasopharyngeal carcinoma receiving a standard treatment of 7000 cGy external beam irradiation have a mean disease free survival of about 1.5 years. In this paper we describe 10 of these patients which were treated with additional peritumoural and intratumoural injections with 3 x 10^4 U IL-2 on 5 days in weeks 2, 4, and 6 of the 7 weeks' irradiation period. This combined treatment group was compared with a historical group of patients treated with standard irradiation alone. Local IL-2 therapy showed a marked clinical and statistical significant improvement of disease-free survival. After five years 63% of the IL-2 treated patients were disease-free versus 8% of the control patients. These results suggest that the therapeutic results of radiotherapy can be significantly improved by combining it with local IL-2 treatment. To our knowledge, this is the first clinical report showing that local IL-2 therapy is effective against an infiltrative and locally metastasizing tumour in human patients. Publication Types: Clinical Trial, Phase I, Phase II

Jacobs et al. (2005) Cancer Immunology, Immunotherapy 54, 792-8

This research will be highlighted in the october 2005 edition of nature clinical practices oncology

tumour type

Interleukin-2 (IL-2) Mechanism of IL-2 therapy of cancer Cancers sensitve to IL-2 Surgery and IL-2 Radiotherapy and IL-2 Chemotherapy and IL-2 Experts I want to co-operate (doctors) Frequently Asked Questions (FAQs)

Information for doctors Information for patients I want to support this research or  more information on the EPTI fund supporting this research

Our research is supported by Stichting ter bevordering van het onderzoek in de Experimentele Pathologie en in het bijzonder in de TumourImmunologie. Stichting EPTI, IJselstein, The Netherlands